![Philippe Archinard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philippe Archinard
Direktor/Vorstandsmitglied bei
GENEURO SA
Vermögen: 550 206 $ am 31.05.2026
Profil
Philippe Archinard currently works at Institut Mérieux SA, as Deputy CEO-Innovation & Scientific Partnerships from 2021, BioAster, as Chairman, bioMérieux SA, as Non-Independent Director from 2005, Advanced BioScience Laboratories, Inc., as Director, bioMERIEUX Benelux SANV, as Director from 2010, Transgene, Inc., as Director, Fondation FINOVI, as Director, Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., as Director, GeNeuro SA (Switzerland), as Independent Director from 2021, NH TherAguix SAS, as Independent Director from 2019, Jalon Therapeutics, as Director, and PHAXIAM Therapeutics SA, as Independent Director from 2023.
Dr. Archinard also formerly worked at Fujirebio Europe NV, as Chief Executive Officer from 2000 to 2010, TSGH SAS, as Chief Executive Officer from 2010 to 2021, bioMérieux, Inc., as Chairman, Lyonbiopôle, as Chairman, Fabentech SAS, as Chairman-Supervisory Board, ERYTech Pharma SA, as Director in 2013, Synergie Lyon Cancer, as Director, École Supérieure de Chimie Physique Électronique, as Director, Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., as Director, and Transgene SA, as Director from 2020 to 2025.
Dr. Archinard received his undergraduate degree and doctorate degree from the University of Lyon and undergraduate degree from Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TRANSGENE SA 0,2 % | 31.12.2024 | 564.661 ( 0,2 % ) | 550 206 $ | 31.05.2026 |
Aktive Positionen von Philippe Archinard
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOMÉRIEUX | Direktor/Vorstandsmitglied | 01.01.2005 |
| NH THERAGUIX SAS | Direktor/Vorstandsmitglied | 22.02.2019 |
| GENEURO SA | Direktor/Vorstandsmitglied | 27.05.2021 |
| PHAXIAM THERAPEUTICS S.A. | Direktor/Vorstandsmitglied | 23.06.2023 |
Transgene, Inc.
 Transgene, Inc. Founded in 1982, Transgene, Inc. is a clinical-stage biotechnology company specializing in cancer immunotherapy through viral vector engineering. The company is based in Dover, DE. The company develops individualized therapeutic vaccines using its proprietary myvac® platform, which designs personalized vaccines targeting tumor-specific neoantigens to stimulate the patient’s immune system against early-stage solid tumors. Its lead product, TG4050, is an individualized neoantigen vaccine in randomized phase 1/2 trials as an adjuvant treatment for HPV-negative head and neck squamous cell carcinoma. Transgene’s pipeline also includes oncolytic virus candidates BT-001 and TG6050, engineered to express immune-modulating antibodies and cytokines, evaluated in early-phase clinical trials for various solid tumors. | Direktor/Vorstandsmitglied | - |
Jalon Therapeutics
 Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Develops medicines for cancer patients | Direktor/Vorstandsmitglied | - |
bioMERIEUX Benelux SANV
 bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology Specializes in vitro diagnostics for medical and industrial applications | Direktor/Vorstandsmitglied | 10.06.2010 |
Institut Mérieux SA
 Institut Mérieux SA BiotechnologyHealth Technology Provides solutions for multifactorial management of diseases | Corporate Officer/Principal | 01.01.2021 |
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd. | Direktor/Vorstandsmitglied | - |
| ░░░░░░░░ | ░░░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ehemalige bekannte Positionen von Philippe Archinard
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ ░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ ░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Philippe Archinard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
24
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 24 |
|---|---|
Transgene SA
 Transgene SA BiotechnologyHealth Technology Designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer | Health Technology |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Develops and markets diagnostic products to improve therapy management and patient health | Health Technology |
bioMérieux SA
 bioMérieux SA Medical SpecialtiesHealth Technology Develops biotechnological products specializing in in-vitro diagnostics and infectious diseases | Health Technology |
TSGH SAS
 TSGH SAS Financial ConglomeratesFinance Functions as an investment holding company | Finance |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Health Technology |
bioMérieux, Inc.
 bioMérieux, Inc. Medical SpecialtiesHealth Technology Develops in-vitro diagnostics solutions | Health Technology |
Advanced BioScience Laboratories, Inc.
 Advanced BioScience Laboratories, Inc. BiotechnologyHealth Technology Operates as a contract development and manufacturing organization dedicated to advancing therapeutics, vaccines & biological products | Health Technology |
University of Lyon
 University of Lyon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology Specializes in vitro diagnostics for medical and industrial applications | Health Technology |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Provides solutions for multifactorial management of diseases | Health Technology |
Synergie Lyon Cancer
 Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Engages in research and development in therapeutic approaches | Commercial Services |
École Supérieure de Chimie Physique Électronique
 École Supérieure de Chimie Physique Électronique Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Transgene, Inc.
Transgene, Inc. Founded in 1982, Transgene, Inc. is a clinical-stage biotechnology company specializing in cancer immunotherapy through viral vector engineering. The company is based in Dover, DE. The company develops individualized therapeutic vaccines using its proprietary myvac® platform, which designs personalized vaccines targeting tumor-specific neoantigens to stimulate the patient’s immune system against early-stage solid tumors. Its lead product, TG4050, is an individualized neoantigen vaccine in randomized phase 1/2 trials as an adjuvant treatment for HPV-negative head and neck squamous cell carcinoma. Transgene’s pipeline also includes oncolytic virus candidates BT-001 and TG6050, engineered to express immune-modulating antibodies and cytokines, evaluated in early-phase clinical trials for various solid tumors. | |
Lyonbiopôle
 Lyonbiopôle Miscellaneous Commercial ServicesCommercial Services Engages in research and biotechnology services for cure of infectious deceases | Commercial Services |
Fondation FINOVI | |
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd.
 Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Researches, develops and manufactures immunotherapies for the treatment of oncology and infectious diseases | Commercial Services |
BioAster
 BioAster Miscellaneous Commercial ServicesCommercial Services Operates as a research institute | Commercial Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fabentech SAS
 Fabentech SAS Medical/Nursing ServicesHealth Services Developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. | Health Services |
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd. | |
GeNeuro SA (Switzerland)
 GeNeuro SA (Switzerland) BiotechnologyHealth Technology Engages in the research and development of pharmaceutical products to treat neurological diseases | Health Technology |
NH TherAguix SAS
 NH TherAguix SAS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops nanomedicine for cancer, combining imaging and radiotherapy | Health Technology |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Develops medicines for cancer patients | Health Technology |
PHAXIAM Therapeutics SA
 PHAXIAM Therapeutics SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops red blood cell-based therapeutics for severe forms of cancer & orphan diseases | Health Technology |
